A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

Breast Cancer Research and Treatment

Volumn 129, Issue 3, 2011, Pages 819-827

  Massarweh, Suleiman ^a,b   Tham, Yee L ^c   Huang, Jian ^c   Sexton, Krystal ^c   Weiss, Heidi ^b   Tsimelzon, Anna ^c   Beyer, Amanda ^c   Rimawi, Mothaffar ^c   Cai, Wei Yen ^c   Hilsenbeck, Susan ^c   Fuqua, Suzanne ^c   Elledge, Richard ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; EGFR; Endocrine resistance; Estrogen receptor; Proliferation

Indexed keywords

ANASTROZOLE; CYCLIN D1; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; LIVER FUNCTION TEST; MALE; MICROARRAY ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUMOR BIOPSY; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CELL CYCLE; CYCLIN D1; ESTRADIOL; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOADJUVANT THERAPY; NITRILES; ONCOGENE PROTEIN V-AKT; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIAZOLES;

EID: 80052602648     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1679-8     Document Type: Article

References (38)

1. EBCTCG 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
2. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher DL Wickerham M Begovic A DeCillis A Robidoux, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 8 2672 2685 9704717 1:CAS:528:DyaK1cXlsFCgurg%3D (Pubitemid 28363030)
3. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra RL Theriault G Singh SM Binkley N Sneige, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 2 460 469 10080586 1:CAS:528:DyaK1MXht1Wmur4%3D (Pubitemid 29075229)
4. AC Braud B Asselain S Scholl A De La Rochefordiere T Palangie V Dieras JY Pierga T Dorval M Jouve P Beuzeboc, et al. 1999 Neoadjuvant chemotherapy in young breast cancer patients: correlation between response and relapse? Eur J Cancer 35 3 392 397 10448288 10.1016/S0959-8049(98)00393-1 1:CAS:528: DyaK1MXisVGqs7w%3D (Pubitemid 29151934)
5. S Diab R Elledge G Clark 2000 Tumor characteristics and clinical outcome of elderly women with breast cancer J Natl Cancer Inst 92 7 550 556 10749910 10.1093/jnci/92.7.550 1:STN:280:DC%2BD3c3hsFSgsg%3D%3D (Pubitemid 30212316)
6. S Paik G Tang S Shak C Kim J Baker W Kim M Cronin FL Baehner D Watson J Bryant, et al. 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 23 3726 3734 16720680 10.1200/JCO.2005.04.7985 1:CAS:528:DC%2BD28XpsVaqsrs%3D (Pubitemid 46622311)
7. CK Osborne 1999 Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer Endocr Relat Cancer 6 2 271 276 10731120 10.1677/erc.0.0060271 1:CAS:528:DyaK1MXktVygtbc%3D (Pubitemid 29260063)
8. C Osborne A Wakeling R Nicholson 2004 Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action Br J Cancer 90 Suppl 1 S2 S6 15094757 10.1038/sj.bjc.6601629 1:CAS:528:DC%2BD2cXjtFaktbY%3D (Pubitemid 38482618)
9. MJ Ellis 2001 Neoadjuvant endocrine therapy for breast cancer: medical perspectives Clin Cancer Res 7 12 Suppl 4388s 4391s 11916229 1:CAS:528:DC%2BD38Xltlyjuw%3D%3D discussion 4411s-4412s (Pubitemid 34031584)
10. IE Smith M Dowsett SR Ebbs JM Dixon A Skene J-U Blohmer SE Ashley S Francis I Boeddinghaus G Walsh 2005 Neoadjuvant treatment of postmenopausal breast cancer patients with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 22 5108 5116 15998903 10.1200/JCO.2005.04.005 1:CAS:528:DC%2BD2MXpsFWmtLY%3D (Pubitemid 46224019)
11. S Massarweh CK Osborne S Jiang AE Wakeling M Rimawi SK Mohsin S Hilsenbeck R Schiff 2006 Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer Cancer Res 66 16 8266 8273 16912207 10.1158/0008-5472.CAN-05-4045 1:CAS:528:DC%2BD28XotFWqurs%3D (Pubitemid 44299196)
12. Massarweh S, Osborne CK, Weiss H, Schiff R (2007) Estrogen deprivation is crucial for the antitumor effect of fulvestrant and adding the HER inhibitor gefitinib delays acquired resistance in a xenograft model of ER-positive breast cancer. Breast Cancer Res and Treat.In: Proceedings of the 30th Annual SAN ANTONIO BREAST SYMPOSIUM-December 2007, 106 (Supplement 1):Abstract # 2090, S2115
13. RM Elledge GM Clark SAW Fuqua Y-Y Yu DC Allred 1994 p53 Protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer Cancer Res 54 14 3752 3757 8033095 1:STN:280:DyaK2czgs1ersw%3D%3D (Pubitemid 24241192)
14. MJ Ellis A Coop B Singh L Mauriac A Llombert-Cussac F Janicke WR Miller DB Evans M Dugan C Brady, et al. 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 18 3808 3816 11559718 1:CAS:528:DC%2BD3MXnsVKqsbo%3D (Pubitemid 32880059)
15. C Li WH Wong 2001 Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection PNAS 98 1 31 36 11134512 10.1073/pnas.011404098 1:CAS:528:DC%2BD3MXkslKnuw%3D%3D (Pubitemid 32095858)
16. Y Benjamini Y Hochberg 1995 Controlling the false discovery rate-a practical and powerful approach to multiple testing J R Stat Soc Ser B Methodol 57 1 289 300
17. P Pavlidis J Qin V Arango JJ Mann E Sibille 2004 Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex Neurochem Res 29 6 1213 1222 15176478 10.1023/B:NERE.0000023608.29741.45 1:CAS:528:DC%2BD2cXjtVWmtLY%3D (Pubitemid 39023495)
18. RM Elledge S Green L Howes GM Clark M Berardo DC Allred R Pugh D Ciocca P Ravdin J O'Sullivan, et al. 1997 Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study J Clin Oncol 15 5 1916 1922 9164202 1:CAS:528:DyaK2sXjsVCksL8%3D (Pubitemid 27209521)
19. DR Ciocca R Elledge 2000 Molecular markers for predicting response to tamoxifen in breast cancer patients Endocrine 13 1 1 10 11051041 10.1385/ENDO:13:1:1 1:CAS:528:DC%2BD3cXms1ygurg%3D
20. R Hui AL Cornish RA McClelland JF Robertson RW Blamey EA Musgrove RI Nicholson RL Sutherland 1996 Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer Clin Cancer Res 2 6 923 928 9816251 1:CAS:528:DyaK28XjvVyrtLg%3D (Pubitemid 26198461)
21. J Shou S Massarweh C Osborne A Wakeling S Ali H Weiss R Schiff 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 12 926 935 15199112 10.1093/jnci/djh166 1:CAS:528:DC%2BD2cXltVWmtLY%3D (Pubitemid 38868139)
22. A Howell J Bergh 2010 Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer J Clin Oncol 28 30 4548 4550 20855842 10.1200/JCO.2010.30.6266 1:CAS:528:DC%2BC3cXhsFaitL7L
23. M Dowsett IE Smith SR Ebbs JM Dixon A Skene R A'Hern J Salter S Detre M Hills G Walsh 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 2 167 170 17228000 10.1093/jnci/djk020 1:CAS:528:DC%2BD2sXhvVOhtbc%3D
24. J Lamb MH Ladha C McMahon RL Sutherland ME Ewen 2000 Regulation of the functional interaction between cyclin D1 and the estrogen receptor Mol Cell Biol 20 23 8667 8675 11073968 10.1128/MCB.20.23.8667-8675.2000 1:CAS:528: DC%2BD3MXitFGkurY%3D (Pubitemid 32245900)
25. A Lebeau A Unholzer G Amann M Kronawitter I Bauerfeind A Sendelhofert A Iff U Lohrs 2003 EGFR, HER-2/neu, cyclin D1, p21, and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast Breast Cancer Res Treat 79 2 187 198 12825853 10.1023/A: 1023958324448 1:CAS:528:DC%2BD3sXktV2quro%3D (Pubitemid 36649168)
26. RL Kilker MD Planas-Silva 2006 Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells Cancer Res 66 23 11478 11484 17145896 10.1158/0008-5472.CAN-06-1755 1:CAS:528: DC%2BD28Xht1KnsLrP (Pubitemid 46009981)
27. FS Kenny R Hui EA Musgrove JM Gee RW Blamey RI Nicholson RL Sutherland JF Robertson 1999 Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer Clin Cancer Res 5 8 2069 2076 10473088 1:STN:280:DyaK1MvgtVSltQ%3D%3D (Pubitemid 29399260)
28. M Guix N de Matos Granja I Meszoely TB Adkins BM Wieman KE Frierson V Sanchez ME Sanders AM Grau IA Mayer, et al. 2008 Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers J Clin Oncol 26 6 897 906 18180460 10.1200/JCO.2007.13.5939 1:CAS:528:DC%2BD1cXjtFeltr8%3D (Pubitemid 351398082)
29. MF Rimawi PB Shetty HL Weiss R Schiff CK Osborne GC Chamness RM Elledge 2010 Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes Cancer 116 5 1234 1242 20082448 10.1002/cncr.24816
30. S Massarweh R Schiff 2006 Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk Endocr Relat Cancer 13 Suppl 1 S15 S24 17259554 10.1677/erc.1.01273 1:CAS:528:DC%2BD2sXivF2mtLk%3D (Pubitemid 46219245)
31. A Polychronis HD Sinnett D Hadjiminas H Singhal JL Mansi D Shivapatham S Shousha J Jiang D Peston N Barrett, et al. 2005 Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial Lancet Oncol 6 6 383 391 15925816 10.1016/S1470-2045(05)70176-5 1:CAS:528:DC%2BD2MXltFWktL0%3D (Pubitemid 40753744)
32. IE Smith G Walsh A Skene A Llombart JI Mayordomo S Detre J Salter E Clark P Magill M Dowsett 2007 A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer J Clin Oncol 25 25 3816 3822 17679728 10.1200/JCO.2006.09.6578 1:CAS:528:DC%2BD2sXhtFanu7zJ (Pubitemid 47477255)
33. M Cristofanilli V Valero A Mangalik M Royce I Rabinowitz FP Arena JF Kroener E Curcio C Watkins S Bacus, et al. 2010 Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer Clin Cancer Res 16 6 1904 1914 20215537 10.1158/1078-0432.CCR-09-2282 1:CAS:528:DC%2BC3cXjtFyhurs%3D
34. CK Osborne P Neven LY Dirix JR Mackey J Robert C Underhill R Schiff C Gutierrez I Migliaccio VK Anagnostou, et al. 2011 Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study Clin Cancer Res 17 5 1147 1159 21220480 10.1158/1078-0432.CCR-10-1869 1:CAS:528:DC%2BC3MXis1eitrk%3D
35. B Kaufman JR Mackey MR Clemens PP Bapsy A Vaid A Wardley S Tjulandin M Jahn M Lehle A Feyereislova, et al. 2009 Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 33 5529 5537 19786670 10.1200/JCO.2008.20.6847 1:CAS:528:DC%2BC3cXhtVWit78%3D
36. S Johnston J Pippen Jr X Pivot M Lichinitser S Sadeghi V Dieras HL Gomez G Romieu A Manikhas MJ Kennedy, et al. 2009 Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 33 5538 5546 19786658 10.1200/JCO.2009.23.3734 1:CAS:528:DC%2BC3cXhtVWit7w%3D
37. J Bayliss A Hilger P Vishnu K Diehl D El-Ashry 2007 Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response Clin Cancer Res 13 23 7029 7036 18056179 10.1158/1078-0432.CCR-07-0587 1:CAS:528:DC%2BD2sXhtlyitL%2FM (Pubitemid 350276884)
38. S Massarweh CK Osborne CJ Creighton L Qin A Tsimelzon S Huang H Weiss M Rimawi R Schiff 2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function Cancer Res 68 3 826 833 18245484 10.1158/0008-5472.CAN-07-2707 1:CAS:528:DC%2BD1cXhtlygtrY%3D (Pubitemid 351206760)